Anti-α-synuclein antibodies may be triggered by an inflammatory CNS microenvironment, frequently present in AD and PD [26], [27], [35], [36] and related to the amount of α-synuclein aggregation and tissue deposition, which is likely extensive in early DLB, in contrast to AD where α-synuclein burden may slowly rise. This evidence concerns the gene SNCA and Alzheimer disease.